Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.47 |
| ▸ | CCNC | P24863 | 8/20 | 0.44 |
| ▸ | CDK8 | P49336 | 8/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10138302 | 0.88 | SLC22A12 (0.51) | SLC22A12CCNCCDK8ARMAP2K7 | |
| SCHEMBL14806656 | 0.85 | SLC22A12 (0.51) | SLC22A12CCNCCDK8ARMAP2K7 | |
| SCHEMBL10138316 | 0.83 | SLC22A12 (0.51) | SLC22A12CCNCCDK8ARMKNK1 | |
| SCHEMBL10138336 | 0.81 | SLC22A12 (0.54) | SLC22A12CCNCCDK8ARMKNK1 | |
| SCHEMBL10138319 | 0.81 | SLC22A12 (0.54) | SLC22A12CCNCCDK8ARMKNK1 | |
| SCHEMBL578479 | 0.80 | SLC22A12 (0.55) | SLC22A12CCNCCDK8ARMKNK1 | |
| SCHEMBL578341 | 0.79 | MAP4K4 (0.58) | SLC22A12CCNCCDK8ARMKNK1 | |
| SCHEMBL578353 | 0.79 | CHEK2 (0.55) | SLC22A12CCNCCDK8ARMKNK1 | |
| SCHEMBL578458 | 0.79 | SLC22A12 (0.45) | SLC22A12CCNCCDK8AR | |
| SCHEMBL578459 | 0.79 | SLC22A12 (0.45) | SLC22A12CCNCCDK8AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418203-B1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO CO LTD (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010116915-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | 第一三共株式会社 (JP) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | BMP2, BMP4, BMP6 | SLC22A12 1300/4885CCNC 1592/4885CDK8 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.